NOV 15, 2018 10:30 AM PST

Cervical Cancer: Everlasting World Health Challenge

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • President, Global Academy for Women's Health and Director at BioSciCon, Inc.
    Biography
      Dr. Olivera Markovic is a medical doctor, Ph.D in biomedical sciences, academician, cancer research scientist, entrepreneur and author. She is President of Global Academy for Women's Health and Director of BioSciCon, Inc.

      Dr. Markovic is experienced academician being elected professor/visiting/adjunct professor at six universities/medical schools: Universities in Belgrade and Skopje (Former Yugoslavia), Medical College of Pennsylvania (now Drexel University, Philadelphia, PA), Georgetown University, American University (Washington, DC), and University of Maryland Baltimore County (Baltimore, MD).

      Teaching was her vocation for 30 years, and she taught students from undergraduate, graduate, doctoral and postdoctoral level, including adult education. She taught basic medical sciences at medical schools, and science courses in colleges and universities in Washington Metro Area (Biochemistry, Biochemistry and Health, General Biology, Anatomy and Physiology, Pathophysiology, Human Body in Health and Disease, Clinical Chemistry, Biotechnology). She has long experience of reviewing the work of others, including student's projects, master and doctoral theses, scientific papers and books. Invited speaker for many national and international meetings.

      During the last two decades, her research interest has been devoted to the improvement of the methodology for early cervical cancer detection and making it available to women around the world. She and Dr. Nenad Markovic developed a new biomarker-based, IT/mobile empowered, infrastructure independent MarkPap(r) platform technology. Supported by NIH, they conducted translational research from an idea to commercial MarkPap® line of products and proposed a new strategy for fighting this disease globally. Cervical cancer is completely preventable and curable disease IF detected on time by screening.

      Dr. Markovic authored more than 200 scientific publications including books, chapters in books, invited review articles, scientific papers and patents. Author of the book "What every woman should know about cervical cancer", Springer 2008, 2010. The Second updated and extended edition was published in 2017 http://www.springer.com/biomed/cancer/book/978-1-4020-6936-9 www.amazon.com

      Global Academy for Women's Health is a non-profit organization with a mission to advance science and education in women's health globally (www.markpap.com). In August 2018, together with BioSciCon, awarded with the healthcare and pharmaceutical award Best for Women's Health Promotion Maryland by Global Health and Pharma.

    Abstract

    The main problem for insufficient cervical cancer screening globally (less than 20% women at risk) is outreach failure. Enabling POCs with modern IT/mobile technology and connecting them with remote medical centers could solve the problem.

    The Global Academy for Women's Health has studied this problem and has proposed one option for its solving this problem and its solution. The optimism for success is coming from the improved Pap test, the new MarkPap(r) test and platform technology offering a composite biomarker which provides instant evaluation of metabolic, cancerogenic and HPV effects on the specimen. It is both cytological and HPV disease testing (dual testing) in one test. It enable IT exchange of files and protocols for global networking via mobile and Internet connection between scattered POC and medical centers and with a protocol for turn-around of data within hours and timely intervention. The specimen is processed in the local POC and Images are transmitted by cell phone camera (Mobile Pap) for evaluation. Further, the presence of this biomarker allows home specimen collection and mailing the specimen to the local POC. This is a dramatic increase in the outreach for screening enabling women living in rural areas, far from medical institutions of any kind, to participate in screening. As announced, this program is aimed to start in parallel with developing local infrastructure enabling sustainability of the new developments. This is exactly according to the recommendation of WHO and dr Tadros Adhanom Ghebreyesus, Director General of WHO, who is acquainted with our work and supports our initiative.


    Show Resources
    You May Also Like
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    NOV 18, 2019 7:00 AM PST
    C.E. CREDITS
    NOV 18, 2019 7:00 AM PST
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    JUN 09, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
    MAR 03, 2020 9:00 AM JST
    C.E. CREDITS
    MAR 03, 2020 9:00 AM JST
    DATE: March 3, 2020 TIME: 9:00am JST A major limitation in the ex vivo expansion of harvested human hematopoietic stem-progenitor cells (HSPCs) is the rapid differentiation of HSPCs at the e...
    FEB 25, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 25, 2020 9:00 AM PST
    Learn about how to generate a small scale CAR-T workflow using ThermoFisher products See detailed characterization tools that can be utilized and applied in a CAR-T workflow...
    Loading Comments...
    Show Resources